Orexina y sus aplicaciones en la clínica
Keywords:
orexinas, neurotransmisores, enzimas, narcolepsiaAbstract
Las orexinas, también llamadas hipocretinas, son neurotransmisores peptídicos que se encuentran en una pequeña población de neuronas del hipotálamo descritos por primera vez hace más de 20 años (Sakurai et al., 1998; De Lecea et al., 1998). Se ha estimado un total de 1,500 neuronas orexigénicas en el cerebro del ratón (De la Herrán-Arita et al., 2011), y de 50,000 a 80,000 en el cerebro humano (Ohno y Sakurai, 2008).
Downloads
References
Baccari, M.C. (2010). Orexins and gastrointestinal functions. Curr. Protein. Pept. Sci. 11(2):148-155.
Baimel, C., Bartlett, S.E., Chiou, L.C., et al. (2015). Orexin/hypocretin role in reward: implications for opioid and other addictions. British Journal of Pharmacology. 172:334-348.
Butterick, T.A., Billington, C.J., Kotz, C.M., et al. (2013). Orexin: pathways to obesity resistance? Rev. Endocrinol. Metab. Disord. 14(4):357-364.
Cason, A.M., y Aston-Jones, G. (2013). Attenuation of saccharin-seeking in rats by orexin/hypocretin receptor 1 antagonist. Psychopharmacology. 228(3):499-507.
Cason, A.M., y Aston-Jones, G. (2014). Role of orexin/ hypocretin in conditioned sucrose-seeking in female rats. Neuropharmacology. 86:97-102.
Chemelli, R., Willie, J., Sinton, C., et al. (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 98(4):437-51.
Chen, Q., De Lecea, L., Hu, Z., et al. (2015). The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Medicinal Research Reviews. 35(1):152-197.
De la Herrán-Arita, A.K., Zomosa-Signoret, V.C., Millán-Aldaco, D.A., et al. (2011). Aspects of the narcolepsy-cataplexy syndrome in O/E3-null mutant mice. Neuroscience. 183:134-143.
De Lecea, L., Kilduff, T., Peyron, C., et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA. 95(1):322-327.
Dubey, A.K., Handu, S.S., y Mediratta, P. (2015). Suvorexant: The first orexin receptor antagonist to treat insomnia. J. Pharmacol. Pharmacother. 6(2):118-121.
Harris, G.C., Wimmer, M., y Aston-Jones, G. (2005). A rolefor lateral hypothalamic orexin neurons in reward seeking. Nature. 437(7058):556-559.
Heifetz, A., Bodkin, M.J., y Biggin, P.C. (2015). Discovery of the first selective, nonpeptidic orexin 2 receptor agonists. J. Med. Chem. 58(20):7928-7930.
Hu, B., Yang, N., Qiao, Q.C., et al. (2015). Roles of the orexin system in central motor control. Neurosci. Biobehav. Rev. 49:43-54.
Katsuki, H., y Michinaga, S. (2012). Anti-Parkinson drugs and orexin neurons. Vitam. Horm. 89:279-290.
Koob, G.F. (2009). Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology. 56(1):18-31.
Korczynski, W., Ceregrzyn, M., Matyjek, R., et al. (2006). Central and local (enteric) action of orexins. J. Physiol. Pharmacol. 57(6):17-42.
Lin, L., Faraco, J., Li, R., et al. (1999). The sleep disorder narcolepsy is caused by a mutation in the hypocretin (orexin) receptor2gene.Cell. 6(98):365-376.
Marcus, J., Aschkenasi, C., Lee, C., et al. (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435(1):6-25.
Martin-Fardon, R., y Weiss, F. (2014). Blockade of hypocretin receptor-1 preferentially prevents cocaine seeking: comparison withnaturalrewardseeking.Neuroreport. 25(7):485-488.
Martynska, L., Wolinska-Witort, E., Chmielowska, M., et al. (2005).Thephysiologicalroleoforexins.NeuroendocrinolLett. 26:289-292.
Nagahara, T., Sautoh, T., Kutsumura, N., et al. (2015). Design and synthesis of non-peptide, selective orexin receptor 2 agonists. J. Med.Chem. 58(20):7931-7937.
Ohno,K.,ySakurai,T.(2008).Orexinneuronalcircuitry:Rolein the regulation of sleep and wakefulness. Frontiers in Neuroendocrinology. 29:70-87.
Organización Mundial de la Salud. (2018). Obesidad y sobrepeso.Disponibleen:http://www.who.int/mediacentre/factsheets/ fs311/es/.
Reichelt, A.C., Westbrook, R.F., y Morris, M.J. (2015). Integration of rewards signaling and appetite regulating peptides systems in the control of food-cue responses. Br. J. Pharmacol. 172(22):5225-5238.
Rhyne, D.N., y Anderson, S.L. (2015). Suvorexant in insomnia: efficacy,safetyandplaceintherapy.TherAdv. Drug. Saf. 6(5): 189-195.
Rodgers, R.J., Wright, F.L., Snow, N.F., et al. (2013). Orexin-1 receptor antagonism fails to reduce anxiety-like behavior in either plus-maze-naïve or plus-maze-experienced mice. Bhev. Brain Res. 243:213-219.
Roh,J.H.,Jiang,J.,Finn,M.B.,etal.(2014).Potentialroleoforexin and sleep modulation in the pathogenesis of Alzherimer’s disease. J. Exp. Med. 211(13):2487-2496.
Roth,T.(2007).Insomnia:Definition,prevalence,etiologyand consequences. J. Clin. Sleep. Med. 3:S7-10.
Sakurai, T., Amemiya, A., Ishii, M., et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 92(4):573-585.
Sakurai,T.,Moriguchi,T.,Furuya,K.,etal.(1999).Structureand function of the prepro-orexin gene. Journal of Biological Chemistry. 274(25):17771-17776.
Sakurai, T., Nagata, R., Yamanaka, A., et al. (2005). Input of orexin/hypocretin neurons revealed by a genetically enconded tracer in mice. Neuron. 46(2):297-308.
Sakurai, T. (2007). The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nature Reviews Neuroscience. 8:171-181.
Scammell, T., y Saper, C. (2007). Orexins: looping forward to slepp, back at addiction. Nat. Med. 13:126-128.
Schmeichel, B.E., Barbier, E., Misra, K.K., et al. (2015). Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats. Neuropsychopharmacology. 40(5):1123-1129.
Steiner, M.A., Sciarretta, C., y Pasquali, A. (2013). The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol. 4:165.
Szabadi, E. (2014). Selective targets for arousal-modifying drugs: implications for the treatment of sleep disorders. Drug DiscoveryToday. 19(5):701-708.
Tanaka, S. (2012). Transcriptional regulation of the hypocretin/orexin gene. Vitam. Horm. 89:75-90.
Tsujino, N., y Sakurai, T. (2013). Role of orexin in modulating arousal, feeding and motivation. Front. Behav. Neurosci. 7:28.
Valiante, S., Liguori, G., Tafuri, S., et al. (2015). Expression and potential role of the peptide orexin-A in prostate cancer. Biochem. Biophys. Res. Commun. 464(4):1290-1296.
Xu, T.R., Yang, Y., Ward, R., et al. (2013). Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cell Signal. 25(12):2413-2423.
Zhou, L., Sun, W.L., y See, R.E. (2011). Orexin receptor targets for anti-relapse medication development in drug addiction. Pharmaceuticals. 4:804-821.
Ziólkowski, M., Czarnecki, D., Budzynski, J., et al. (2015). Orexin in patients with alcohol dependence treated for relapse prevention: A pilot study. Alcohol Alcohol. pii: agv129.
